Researchers are studying whether GLP-1 drugs, which act on mood, appetite and reward pathways, could help with depression, addiction and binge eating.
Recap by typeshit. Full story at News-Medical.
A retrospective cohort checks whether retinal disease started or worsened more in established users than in people never on either drug, plus a regional NAION review.
24:34
An animated explainer walking through what semaglutide does in the body, from appetite signals in the brain to digestion and blood sugar control.
A CHEST 2026 records analysis of roughly 2 million patients found 1.4% versus 2.3% at one year. The authors say it shows an association, not proof the drugs caused it.
In rats and minipigs, doses too small to cut weight still reduced heart scarring and stiffness tied to a common heart failure type, researchers report.
At the SIO congress in Palermo, specialists flagged short real-world adherence and no national reimbursement in Italy. Oral semaglutide and orforglipron are expected there in 2027.
Dr. Nadolsky, an obesity medicine doctor, gives his take on a recent GLP-1 warning in a short clip. Tap through to see which warning he means.
Loading…